Inex Innovations Licenses NIPT Technology From A*STAR

Nov 20, 2017

|

NEW YORK (GenomeWeb) – Molecular diagnostics firm Inex Innovations Exchange announced today that it has exclusively licensed non-invasive prenatal testing (NIPT) technology from Singapore's Agency for Science, Technology, and Research (A*STAR).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Free of Influence

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

Avoiding the MARCH1 to 1-Mar Change

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

Nature Papers Reveal Tuatara Genome, Cell Populations Involved in Lupus

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

Overlooked Expertise

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

Featured White Papers

GX Solutions – Noise Reduction

GX Solutions: The First Professional Medical-Grade Refrigerators

NGS-Based Target Capture for SARS-CoV-2 Detection and Characterization

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

Aug

18

Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug

27

Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

Menu

Inex Innovations Licenses NIPT Technology From A*STAR

To read the full story....

Breaking News

Fluidigm Q2 Revenues Fall 8 Percent

NantHealth Q2 Revenues Decline 12 Percent

Twist Bioscience Q3 Revenues Grow 56 percent

Guardant Health Q2 Revenues Rise 23 Percent

Illumina Q2 Revenues Drop 25 Percent

Personalis Q2 Revenues Up 23 Percent

The Scan

Free of Influence

Avoiding the MARCH1 to 1-Mar Change

Nature Papers Reveal Tuatara Genome, Cell Populations Involved in Lupus

Overlooked Expertise

Featured White Papers

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Utility of Novel RNA-Based Tools in Oncology Drug Development

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

What's Popular?

Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing

Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Invitae Q2 Revenues Decrease 14 Percent but Beat Street Estimate

Qiagen Q2 Revenues Soar 16 Percent on Coronavirus Testing Product Sales

Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues

Sponsorships